Zobrazeno 1 - 10
of 650
pro vyhledávání: '"Norén GN"'
Autor:
Sartori D; Uppsala Monitoring Centre, Uppsala, Sweden. daniele.sartori@who-umc.org.; Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. daniele.sartori@who-umc.org., Aronson JK; Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Erlanson N; Uppsala Monitoring Centre, Uppsala, Sweden., Norén GN; Uppsala Monitoring Centre, Uppsala, Sweden., Onakpoya IJ; Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Publikováno v:
Drug safety [Drug Saf] 2024 May; Vol. 47 (5), pp. 475-485. Date of Electronic Publication: 2024 Feb 24.
Autor:
Fusaroli M; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy. michele.fusaroli2@unibo.it., Salvo F; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France. francesco.salvo@u-bordeaux.fr.; Service de Pharmacologie Médicale, CHU de Bordeaux, INSERM, U1219, 33000, Bordeaux, France. francesco.salvo@u-bordeaux.fr., Begaud B; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France., AlShammari TM; College of Pharmacy, Almaarefa University, Riyadh, Saudi Arabia., Bate A; Global Safety, GSK, Brentford, UK.; Department of Non-Communicable Epidemiology, London School of Hygiene and Tropical Medicine, London, UK., Battini V; Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano, Milan, Italy., Brueckner A; Novartis Pharma AG, Basel, Switzerland., Candore G; Medical Affairs and Pharmacovigilance, Bayer AG, Berlin, Germany., Carnovale C; Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano, Milan, Italy., Crisafulli S; Department of Medicine, University of Verona, Verona, Italy., Cutroneo PM; Unit of Clinical Pharmacology, Sicily Pharmacovigilance Regional Centre, University Hospital of Messina, Messina, Italy., Dolladille C; UNICAEN, EA4650 SEILIRM, CHU de Caen Normandie, Normandie University, Caen, France.; Department of Pharmacology, CHU de Caen Normandie, Caen, France., Drici MD; Department of Clinical Pharmacology, Université Côte d'Azur Medical Center, Nice, France., Faillie JL; Desbrest Institute of Epidemiology and Public Health, Department of Medical Pharmacology and Toxicology, INSERM, Univ Montpellier, Regional Pharmacovigilance Centre, CHU Montpellier, Montpellier, France., Goldman A; Department of Internal Medicine, Sheba Medical Center, Ramat-Gan, Israel.; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Hauben M; Pfizer Inc, New York, NY, USA.; Department of Family and Community Medicine, New York Medical College, Valhalla, New York, USA., Herdeiro MT; Department of Medical Sciences, IBIMED-Institute of Biomedicine, University of Aveiro, 3810-193, Aveiro, Portugal., Mahaux O; Global Safety, GSK, Brentford, UK., Manlik K; Medical Affairs and Pharmacovigilance, Bayer AG, Berlin, Germany., Montastruc F; Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital (CHU), Toulouse, France.; CIC 1436, Team PEPSS (Pharmacologie En Population cohorteS et biobanqueS), Toulouse University Hospital, Toulouse, France., Noguchi Y; Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan., Norén GN; Uppsala Monitoring Centre, Uppsala, Sweden., Noseda R; Institute of Pharmacological Sciences of Southern Switzerland, Division of Clinical Pharmacology and Toxicology, Ente Ospedaliero Cantonale, Lugano, Switzerland., Onakpoya IJ; Department for Continuing Education, University of Oxford, Oxford, UK., Pariente A; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France.; Service de Pharmacologie Médicale, CHU de Bordeaux, INSERM, U1219, 33000, Bordeaux, France., Poluzzi E; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Salem M; Health Canada, Ottawa, ON, Canada., Sartori D; Uppsala Monitoring Centre, Uppsala, Sweden.; Centre for Evidence-Based Medicine, Nuffield, Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Trinh NTH; PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway., Tuccori M; Tuscany Regional Centre, Unit of Adverse Drug Reaction Monitoring, University Hospital of Pisa, Pisa, Italy., van Hunsel F; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.; PharmacoTherapy, Epidemiology and Economics, University of Groningen, Groningen Research Institute of Pharmacy, Groningen, The Netherlands., van Puijenbroek E; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.; PharmacoTherapy, Epidemiology and Economics, University of Groningen, Groningen Research Institute of Pharmacy, Groningen, The Netherlands., Raschi E; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Khouri C; Pharmacovigilance Department, Université Grenoble Alpes, Grenoble Alpes University Hospital, Grenoble, France.; UMR 1300-HP2 Laboratory, Université Grenoble Alpes, INSERM, Grenoble Alpes University, Grenoble, France.
Publikováno v:
Drug safety [Drug Saf] 2024 Jun; Vol. 47 (6), pp. 585-599. Date of Electronic Publication: 2024 May 07.
Autor:
Fusaroli M; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Salvo F; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France.; Service de Pharmacologie Médicale, CHU de Bordeaux, INSERM, U1219, 33000, Bordeaux, France., Begaud B; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France., AlShammari TM; College of Pharmacy, Almaarefa University, Riyadh, Saudi Arabia., Bate A; Global Safety, GSK, Brentford, UK.; Department of Non-Communicable Epidemiology, London School of Hygiene and Tropical Medicine, London, UK., Battini V; Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano, Milan, Italy., Brueckner A; Novartis, Basel, Switzerland., Candore G; Bayer AG, Medical Affairs and Pharmacovigilance, Berlin, Germany., Carnovale C; Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università degli Studi di Milano, Milan, Italy., Crisafulli S; Department of Medicine, University of Verona, Verona, Italy., Cutroneo PM; Unit of Clinical Pharmacology, Sicily Pharmacovigilance Regional Centre, University Hospital of Messina, Messina, Italy., Dolladille C; UNICAEN, EA4650 SEILIRM, CHU de Caen Normandie, Normandie University, Caen, France.; Department of Pharmacology, CHU de Caen Normandie, Caen, France., Drici MD; Department of Clinical Pharmacology, Université Côte d'Azur Medical Center, Nice, France., Faillie JL; Desbrest Institute of Epidemiology and Public Health, Department of Medical Pharmacology and Toxicology, INSERM, Univ Montpellier, Regional Pharmacovigilance Centre, CHU Montpellier, Montpellier, France., Goldman A; Department of Internal Medicine, Sheba Medical Center, Ramat-Gan, Israel.; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Hauben M; Pfizer Inc., New York, USA.; Department of Family and Community Medicine, New York Medical College, Valhalla, New York, USA., Herdeiro MT; Department of Medical Sciences, IBIMED-Institute of Biomedicine, University of Aveiro, 3810-193, Aveiro, Portugal., Mahaux O; Global Safety, GSK, Brentford, UK., Manlik K; Bayer AG, Medical Affairs and Pharmacovigilance, Berlin, Germany., Montastruc F; Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital (CHU), Toulouse, France.; CIC 1436, Team PEPSS (Pharmacologie En Population cohorteS et biobanqueS), Toulouse University Hospital, Toulouse, France., Noguchi Y; Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan., Norén GN; Uppsala Monitoring Centre, Uppsala, Sweden., Noseda R; Institute of Pharmacological Sciences of Southern Switzerland, Division of Clinical Pharmacology and Toxicology, Ente Ospedaliero Cantonale, Lugano, Switzerland., Onakpoya IJ; Department for Continuing Education, University of Oxford, Oxford, UK., Pariente A; Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France.; Service de Pharmacologie Médicale, CHU de Bordeaux, INSERM, U1219, 33000, Bordeaux, France., Poluzzi E; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Salem M; Health Canada, Ottawa, Canada., Sartori D; Uppsala Monitoring Centre, Uppsala, Sweden.; Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Trinh NTH; PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway., Tuccori M; Tuscany Regional Centre, Unit of Adverse Drug Reaction Monitoring, University Hospital of Pisa, Pisa, Italy., van Hunsel F; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands.; University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology and Economics, Groningen, the Netherlands., van Puijenbroek E; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands.; University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology and Economics, Groningen, the Netherlands., Raschi E; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy. emanuel.raschi@unibo.it., Khouri C; Pharmacovigilance Department, Univ. Grenoble Alpes, Grenoble Alpes University Hospital, Grenoble, France. ckhouri@chu-grenoble.fr.; UMR 1300-HP2 Laboratory, Univ. Grenoble Alpes, INSERM, Grenoble Alpes University, Grenoble, France. ckhouri@chu-grenoble.fr.
Publikováno v:
Drug safety [Drug Saf] 2024 Jun; Vol. 47 (6), pp. 575-584. Date of Electronic Publication: 2024 May 07.
Autor:
Gauffin O; Uppsala Monitoring Centre, Uppsala, Sweden., Brand JS; Uppsala Monitoring Centre, Uppsala, Sweden. judith.brand@who-umc.org., Vidlin SH; Uppsala Monitoring Centre, Uppsala, Sweden., Sartori D; Uppsala Monitoring Centre, Uppsala, Sweden., Asikainen S; BCB Medical Ltd, Turku, Finland., Català M; Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Chalabi E; Heliant Ltd, Belgrade, Serbia., Dedman D; Clinical Practice Research Datalink (CPRD), The Medicines and Healthcare Products Regulatory Agency, London, UK., Danilovic A; CHC Zvezdara, Belgrade, Serbia., Duarte-Salles T; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands., García Morales MT; Instituto de Investigación Sanitaria Hospital 12 de Octubre, CIBER de Epidemiología y Salud Pública, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain., Hiltunen S; BCB Medical Ltd, Espoo, Finland., Jödicke AM; Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Lazarevic M; Clinic for cardiac and transplant surgery, University Clinical Center Nis, Nis, Serbia., Mayer MA; Hospital del Mar Medical Research Institute, Parc de Salut Mar, Barcelona, Spain., Miladinovic J; Clinic for infectious diseases, University Clinical Center Nis, University Clinical Center Nis, Nis, Serbia., Mitchell J; Uppsala Monitoring Centre, Uppsala, Sweden., Pistillo A; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain., Ramírez-Anguita JM; Hospital del Mar Medical Research Institute, Parc de Salut Mar, Barcelona, Spain., Reyes C; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain., Rudolph A; Uppsala Monitoring Centre, Uppsala, Sweden., Sandberg L; Uppsala Monitoring Centre, Uppsala, Sweden., Savage R; Uppsala Monitoring Centre, Uppsala, Sweden.; Department of General Practice, University of Otago, Christchurch, New Zealand., Schuemie M; Epidemiology Department, Johnson & Johnson, Titusville, NJ, USA.; Department of Biostatistics, UCLA, Los Angeles, CA, USA., Spasic D; Clinic for cardiac and transplant surgery, University Clinical Center Nis, Nis, Serbia., Trinh NTH; PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway., Veljkovic N; Heliant Ltd, Belgrade, Serbia.; Vinca Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia., Vujovic A; Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia., de Wilde M; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands., Zekarias A; Uppsala Monitoring Centre, Uppsala, Sweden., Rijnbeek P; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands., Ryan P; Epidemiology Department, Johnson & Johnson, Titusville, NJ, USA.; Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, USA., Prieto-Alhambra D; Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands., Norén GN; Uppsala Monitoring Centre, Uppsala, Sweden.
Publikováno v:
Drug safety [Drug Saf] 2023 Dec; Vol. 46 (12), pp. 1335-1352. Date of Electronic Publication: 2023 Oct 07.
Autor:
Sartori D; Uppsala Monitoring Centre, Uppsala, Sweden. daniele.sartori@who-umc.org.; Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. daniele.sartori@who-umc.org., Aronson JK; Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Norén GN; Uppsala Monitoring Centre, Uppsala, Sweden., Onakpoya IJ; Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Publikováno v:
Drug safety [Drug Saf] 2023 Feb; Vol. 46 (2), pp. 109-120. Date of Electronic Publication: 2022 Dec 05.
Autor:
Ekhart C; Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237, MH's-Hertogenbosch, The Netherlands. c.ekhart@lareb.nl., van Hunsel F; Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237, MH's-Hertogenbosch, The Netherlands.; Groningen Research Institute of Pharmacy, Pharmacotherapy, Epidemiology and Economics, University of Groningen, Groningen, The Netherlands., van Puijenbroek E; Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237, MH's-Hertogenbosch, The Netherlands.; Groningen Research Institute of Pharmacy, Pharmacotherapy, Epidemiology and Economics, University of Groningen, Groningen, The Netherlands., Chandler R; Uppsala Monitoring Centre, Uppsala, Sweden., Meldau EL; Uppsala Monitoring Centre, Uppsala, Sweden., Taavola H; Uppsala Monitoring Centre, Uppsala, Sweden., Norén GN; Uppsala Monitoring Centre, Uppsala, Sweden.
Publikováno v:
Drug safety [Drug Saf] 2022 Feb; Vol. 45 (2), pp. 145-153. Date of Electronic Publication: 2022 Jan 12.
Consensus clustering for case series identification and adverse event profiles in pharmacovigilance.
Autor:
Norén GN; Uppsala Monitoring Centre, Uppsala, Sweden. Electronic address: niklas.noren@who-umc.org., Meldau EL; Uppsala Monitoring Centre, Uppsala, Sweden., Chandler RE; Uppsala Monitoring Centre, Uppsala, Sweden.
Publikováno v:
Artificial intelligence in medicine [Artif Intell Med] 2021 Dec; Vol. 122, pp. 102199. Date of Electronic Publication: 2021 Oct 22.
Autor:
Liles, Elizabeth G.1 Beth.G.Liles@kpchr.org, Irving, Stephanie A.1, Koppolu, Padma1, Crane, Bradley1, Naleway, Allison L.1, Brooks, Neon B.1, Gee, Julianne2, Unger, Elizabeth R.2, Henninger, Michelle L.1
Publikováno v:
Permanente Journal. Sep2024, Vol. 28 Issue 3, p46-57. 12p.
Autor:
Chen, Yuheng1 (AUTHOR), Ren, Xiayang2 (AUTHOR), Dai, Yuanyuan2 (AUTHOR), Wang, Yanfeng3 (AUTHOR) wangyf@cicams.ac.cn
Publikováno v:
Scientific Reports. 9/13/2024, Vol. 14 Issue 1, p1-10. 10p.
Autor:
Kim, Seong Kyung1, Kim, Myeong Gyu1 kimmg@ewha.ac.kr
Publikováno v:
Scientific Reports. 9/3/2024, Vol. 14 Issue 1, p1-7. 7p.